

USSN 09/421,506

AND-1001-UTL1-CON1

AMENDMENT - Claims

**RECEIVED  
CENTRAL FAX CENTER**

JUL 09 2004

**OFFICIAL**

Please amend claims 383 and 388-390, as follows:

383. (currently amended) A method of identifying a T cell specific for an antigen of interest, comprising:

- a) contacting a biological sample containing T cells suspected of being specific for ~~the~~ an antigen of interest with an artificial antigen presenting cell that presents a peptide derived from the antigen of interest in order to form a complex comprised of a T cell specific for the antigen of interest and an artificial antigen presenting cell that presents the peptide derived from the antigen of interest, wherein the artificial antigen presenting cell comprises:
  - i. a liposome comprising a lipid bilayer, wherein the lipid bilayer is comprised of neutral phospholipids and cholesterol;
  - ii. at least one GM-1 ganglioside molecule disposed in the lipid bilayer;
  - iii. a cholera toxin  $\beta$  subunit bound to one of the ~~a~~ GM-1 ganglioside molecules;
  - iv. an MHC ~~component~~ molecule loaded with the peptide derived from the antigen of interest, wherein the antigen-loaded MHC ~~component~~ molecule is bound to the cholera toxin  $\beta$  subunit; and
  - v. an accessory molecule that can stabilize an interaction between a T cell receptor and the antigen-loaded MHC ~~component~~ molecule; and
- b) detecting the complex, if formed, thereby identifying a T cell specific for the antigen of interest.

USSN 09/421,506

AND-1001-UTL1-CON1

384. (previously presented) A method according to claim 383 wherein the neutral phospholipids are phosphatidylcholine.
385. (previously presented) A method according to claim 383 further comprising the step of isolating from the complex the T cell specific for the antigen of interest.
386. (previously presented) A method according to claim 385 further comprising the step of characterizing a functional phenotype of the isolated T cells.
387. (previously presented) A method according to claim 383 wherein the biological sample is selected from the group consisting of whole blood, blood cells, blood plasma, and tissue.
388. (currently amended) A method according to claim 383 wherein the peptide derived from the antigen of interest is selected from the group consisting of ~~a peptide~~, a peptide derived from a recipient of a graft, a cancer cell-derived peptide, a peptide derived from an allergen, a donor-derived peptide, ~~a pathogen-derived molecule~~, and a peptide derived by epitope mapping, ~~a self-derived molecule~~, and ~~a self-derived molecule that has sequence identity with a pathogen-derived antigen~~.
389. (currently amended) A method according to claim 383 wherein the artificial antigen presenting cell also comprises a label.
390. (currently amended) A method according to claim 389 wherein the label is bound to a molecule of the artificial antigen presenting cell selected from the group consisting of a neutral phospholipid, ~~a cholesterol molecule~~, a GM-1 ganglioside molecule, a cholera toxin  $\beta$  subunit, an

USSN 09/421,506

AND-1001-UTL1-CONI

MHC ~~component~~ molecule, the peptide derived from the antigen of interest, and an accessory molecule.

391. (previously presented) A method according to claim 389 wherein the label is selected from the group consisting of biotin, vancomycin, a fluorochrome, FITC, and a radiolabel.